Round cell liposarcoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:36:22 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Round cell liposarcoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Trabectedin alone versus Trabectedin with tTF-NGR combination therapy in adults with metastatic or refractory soft tissue sarcoma who failed first-line treatment https://clinicaltrials.eu/trial/study-on-trabectedin-and-ttf-ngr-for-patients-with-metastatic-or-refractory-soft-tissue-sarcoma/ Wed, 29 Apr 2026 14:59:55 +0000 https://clinicaltrials.eu/trial/study-on-trabectedin-and-ttf-ngr-for-patients-with-metastatic-or-refractory-soft-tissue-sarcoma/ This clinical trial studies a treatment for soft tissue sarcoma, a type of cancer that develops in soft tissues like muscles and fat. The study focuses on patients whose cancer has spread to other parts of the body (metastatic) or who did not respond well to previous treatments. The trial compares two treatment approaches: one using only trabectedin (a chemotherapy medication) and another combining trabectedin with tTF-NGR (an experimental drug).

The study aims to determine if adding tTF-NGR to standard trabectedin treatment helps keep the cancer under control for a longer time. Both medications are given through an intravenous infusion directly into the bloodstream. The experimental drug tTF-NGR is designed to concentrate the chemotherapy medication inside the tumor.

During the study, participants receive treatment for up to 360 days. Some patients will receive only trabectedin, while others will receive both trabectedin and tTF-NGR. Regular medical examinations and imaging tests will be performed to monitor how the cancer responds to the treatment. The study focuses on patients whose tumors show a specific characteristic called CD13 positivity, which is determined through laboratory testing.

]]> Study on the Effectiveness and Safety of INT230-6 (Vinblastine Sulfate, Cisplatin) for Adults with Metastatic Soft Tissue Sarcomas https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-int230-6-vinblastine-sulfate-cisplatin-for-adults-with-metastatic-soft-tissue-sarcomas/ Wed, 29 Apr 2026 14:59:28 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-int230-6-vinblastine-sulfate-cisplatin-for-adults-with-metastatic-soft-tissue-sarcomas/ This clinical trial is focused on studying the effectiveness and safety of a new treatment called INT230-6 for patients with certain types of soft tissue sarcomas. Soft tissue sarcomas are a group of cancers that begin in the tissues that connect, support, or surround other structures and organs of the body. The specific types of sarcomas being studied include liposarcoma, undifferentiated pleomorphic sarcoma, and leiomyosarcoma. The treatment INT230-6 is a combination of two substances, vinblastine sulfate and cisplatin, which are administered directly into the tumor.

The purpose of the study is to compare the new treatment, INT230-6, with the standard care currently used in the United States for these types of sarcomas. Participants in the study will receive either the new treatment or the standard care, which may include other medications such as Halaven, Trabectedin, or Pazopanib. The study will last for a period of up to 24 months, during which the participants’ health and response to the treatment will be closely monitored.

This trial aims to provide valuable information on whether INT230-6 can improve the overall survival of patients with these challenging types of cancer. The study will also look at the side effects and overall quality of life of the participants during the treatment period. By participating in this study, researchers hope to find more effective ways to treat soft tissue sarcomas and improve outcomes for patients in the future.

]]> Study of Afamitresgene Autoleucel for Patients with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma https://clinicaltrials.eu/trial/study-of-afamitresgene-autoleucel-for-patients-with-advanced-synovial-sarcoma-or-myxoid-round-cell-liposarcoma/ Wed, 29 Apr 2026 14:28:35 +0000 https://clinicaltrials.eu/trial/study-of-afamitresgene-autoleucel-for-patients-with-advanced-synovial-sarcoma-or-myxoid-round-cell-liposarcoma/ This clinical trial is focused on studying two types of cancer: Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma. These are rare forms of cancer that affect soft tissues in the body. The treatment being tested in this study is called Afamitresgene autoleucel, which is a type of cell therapy. This treatment involves using genetically modified T cells, which are a part of the immune system, to target and fight the cancer cells.

The purpose of the study is to evaluate how effective this new treatment is for patients with these specific types of cancer. Participants in the study will receive the treatment through an infusion, which means the medicine is given directly into the bloodstream through a vein. The study will follow participants over a period of time to monitor their response to the treatment and any side effects they may experience.

Throughout the study, researchers will collect information on how well the treatment works in shrinking the tumors and improving the patients’ health. They will also keep track of any adverse effects to ensure the safety of the participants. The study aims to provide valuable insights into the potential benefits of Afamitresgene autoleucel for treating these challenging cancers.

]]> Study of Letetresgene Autoleucel for Patients with Synovial Sarcoma and Myxoid/Round Cell Liposarcoma https://clinicaltrials.eu/trial/study-of-letetresgene-autoleucel-for-patients-with-synovial-sarcoma-and-myxoid-round-cell-liposarcoma/ Wed, 29 Apr 2026 14:28:22 +0000 https://clinicaltrials.eu/trial/study-of-letetresgene-autoleucel-for-patients-with-synovial-sarcoma-and-myxoid-round-cell-liposarcoma/ This clinical trial is focused on studying two types of cancer: synovial sarcoma and myxoid/round cell liposarcoma. These are rare forms of cancer that affect soft tissues in the body. The treatment being tested in this study is called GSK3377794, which is a type of cell therapy. This treatment involves using the patient’s own immune cells, specifically T cells, which are modified in a laboratory to better recognize and attack cancer cells. The modified T cells are then infused back into the patient’s body to help fight the cancer.

The purpose of the study is to evaluate how effective and safe this treatment is for patients with these specific types of cancer. Participants in the study will receive the GSK3377794 treatment, and some may also receive other anti-cancer agents. The study will monitor how the cancer responds to the treatment and any side effects that may occur. The treatment is given through an infusion, which means it is delivered directly into the bloodstream through a vein.

Throughout the study, participants will have regular check-ups to assess their health and the progress of the treatment. The study aims to provide valuable information on whether this new approach can help improve outcomes for patients with synovial sarcoma and myxoid/round cell liposarcoma. The study is expected to continue until 2025, allowing researchers to gather comprehensive data on the treatment’s effectiveness and safety.

]]>